Pharmacological inhibition of WNT signaling in tumor cells dependent on WNT ligands for growth (for example, with RNF43 loss-of-function mutations) induces MYC-dependent downregulation of NPM1 and other ribosome biogenesis and rRNA processing factors, identifying NPM1 as a key effector in the WNT–MYC axis23. The gene discussed is MYC; the disease is neoplasm.